Backbone Cyclic Peptidomimetic Melanocortin-4 Receptor Agonist as a Novel Orally Administrated Drug Lead for Treating Obesity-Reference-Cited by-同舟云学术

Backbone Cyclic Peptidomimetic Melanocortin-4 Receptor Agonist as a Novel Orally Administrated Drug Lead for Treating Obesity

Published:2008-01-26 Issue:4 Volume:51 Page:1026-1034
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hess Shmuel¹,Linde Yaniv¹,Ovadia Oded¹,Safrai Eli¹,Shalev Deborah E.¹,Swed Avi¹,Halbfinger Efrat¹,Lapidot Tair¹,Winkler Ilan¹,Gabinet Yael¹,Faier Avi¹,Yarden Dana¹,Xiang Zhimin¹,Portillo Federico P.¹,Haskell-Luevano Carrie¹,Gilon Chaim¹,Hoffman Amnon¹

Affiliation:

1. Department of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 91120, Israel, Institute of Chemistry, and Wolfson Centre for Applied Structural Biology, Safra Campus, Givat Ram, The Hebrew University of Jerusalem, Jerusalem 91904, Israel, Bioline Rx, Jerusalem 91450, Israel, and Department of Medicinal Chemistry, University of Florida, Gainesville, Florida 32610-0485

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm701093y

Reference40 articles.

1. The extent of the problem of obesity

2. Prevalence of Overweight and Obesity in the United States, 1999-2004

3. Melanocortins and body weight: a tale of two receptors

4. Food conversion is transiently affected during 4-week chronic administration of melanocortin agonist and antagonist in rats

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the association between the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, mental health, and cardio-metabolic risk factors among individuals with obesity;BMC Endocrine Disorders;2023-02-02

2. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin;Biomolecules;2022-10-01

3. PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design;Molecular Cancer Therapeutics;2022-09-02

4. Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides;ACS Pharmacology & Translational Science;2022-04-14

5. Mapping of FSHR agonists and antagonists binding sites to identify potential peptidomimetic modulators;Biochimica et Biophysica Acta (BBA) - Biomembranes;2022-04